Appoi tme t st e gthe s fi a cial gove a ce a d suppo ts NeO c’s cli ical developme t a d expa sio i Abu Dhabi
CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) — NeO c Tech ologies Holdi gs, I c. (Nasdaq: NTHI) (“NeO c” o the “Compa y”), a cli ical-stage biopha maceutical compa y developi g the apies fo ce t al e vous system ca ce s, today a ou ced the appoi tme t of Ali Alabedi to its Boa d of Di ecto s, effective Octobe 9, 2026. M . Alabedi is Head of Islamic Ba ki g G oup at Fi st Abu Dhabi Ba k (FAB), the UAE’s la gest ba k a d a majo Gulf ba ki g i stitutio , with AED 1.41 t illio i total assets as of Ju e 30, 2026.
The appoi tme t b i gs se io ba ki g a d gove a ce expe tise to NeO c’s Boa d as the Compa y adva ces its cli ical p og ams a d expa ds its developme t activities i Abu Dhabi. The Depa tme t of Health – Abu Dhabi has g a ted IND autho izatio fo NEO212, suppo ti g the Compa y’s pla s fo Phase 2 developme t i the UAE, subject to equi ed ethics app ovals a d othe p e-e ollme t co ditio s.
“Ali’s appoi tme t st e gthe s ou Boa d as we adva ce ou cli ical p og ams a d build ou p ese ce i Abu Dhabi,” said Ami Heshmatpou , Executive Chai ma , P eside t a d Chief Executive Office of NeO c. “His expe ie ce i fi a cial gove a ce, egulato y e gageme t a d i te atio al g owth will help guide ou ext stage of developme t. We app eciate the Depa tme t of Health – Abu Dhabi’s suppo t fo ou cli ical expa sio a d sha e a commitme t to b i gi g ew t eatme t optio s to patie ts faci g devastati g b ai ca ce s. I look fo wa d to wo ki g with Ali to adva ce that missio a d c eate lo g-te m value fo ou sha eholde s.”
“NeO c is wo ki g to develop t eatme ts fo ca ce s of the b ai that emai amo g the most difficult to t eat,” said M . Alabedi . “I am ho o ed to joi the Boa d a d look fo wa d to co t ibuti g my expe ie ce i gove a ce a d i te atio al g owth as the Compa y adva ces its p og ams.”
M . Alabedi succeeds D . Steve L. Gia otta, who has g aciously stepped dow f om the Boa d a d will co ti ue to se ve o NeO c’s Scie tific Adviso y Boa d. The Compa y tha ks D . Gia otta fo his Boa d se vice a d co ti ued scie tific co t ibutio s.
M . Alabedi has mo e tha th ee decades of i te atio al ba ki g expe ie ce ac oss the Middle East a d Asia Pacific. Si ce 2022, he has se ved as FAB’s Head of Islamic Ba ki g G oup, leadi g its wholesale, i vestme t, etail a d p ivate ba ki g activities a d i te atio al ope atio s.
P eviously, M . Alabedi held se io leade ship oles at Sta da d Cha te ed Ba k, ANZ Ba ki g G oup a d Dubai Islamic Ba k, spa i g fi a cial i stitutio s, co po ate ba ki g, dist ibutio a d st ategic elatio ships. He also fou ded Dubai Islamic Fi a cial Se vices as Chief Executive Office a d subseque tly se ved as a executive boa d membe .
M . Alabedi holds a Maste of I te atio al Busi ess f om the U ive sity of Wollo go g i Aust alia a d completed the Aspi i g Di ecto s P og amme at INSEAD.
NeO c Tech ologies Holdi gs, I c. is a cli ical-stage life scie ces compa y focused o the developme t a d comme cializatio of ce t al e vous system the apeutics that a e desig ed to add ess the pe siste t challe ges i ove comi g the blood-b ai ba ie . The compa y’s NEO™ d ug developme t platfo m has p oduced a po tfolio of ovel d ug ca didates a d delive y methods with pate t p otectio s exte di g to 2038. These p op ieta y chemothe apy age ts have demo st ated positive effects i labo ato y tests o va ious types of ca ce s a d i cli ical t ials t eati g malig a t gliomas. NeO c’s NEO100™ a d NEO212™ the apeutics a e i cli ical developme t. NEO212 has completed Phase 1 dose escalatio a d is adva ci g towa d Phase 2 developme t. The compa y has exclusively lice sed a exte sive wo ldwide pate t po tfolio f om the U ive sity of Southe Califo ia co sisti g of issued pate ts a d pe di g applicatio s elated to NEO100, NEO212, a d othe p oducts f om the NeO c pate t family fo multiple uses, i cludi g o cological a d eu ological co ditio s.
Fo mo e about NeO c a d its pio ee i g tech ology, visit https:// eo c.com.
This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995, i cludi g stateme ts about the Compa y’s cli ical developme t pla s, activities i the U ited A ab Emi ates a d a ticipated be efits of the Boa d appoi tme t. These stateme ts eflect cu e t expectatio s a d a e subject to isks a d u ce tai ties that could cause actual esults to diffe mate ially, i cludi g isks desc ibed i the Compa y’s fili gs with the Secu ities a d Excha ge Commissio .
The Compa y u de takes o obligatio to update a y fo wa d-looki g stateme t except as equi ed by law.
“NEO100” a d “NEO212” a e egiste ed t adema ks of NeO c Tech ologies Holdi gs, I c.
i fo@ eo c.com
Jo Nuge tJo Nuge t Commu icatio sjo @jo uge t.com205-566-3026
This p ess elease was published by a CLEAR® Ve ified i dividual.
